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Introduction 
In RT, multimodality imaging is increasingly combined for  a better 
tumour delineation. The CT has a high geometrical accuracy and 
a direct connection to electron density while the MRI provides 
additional soft-tissue contrast to CT. Registration of MRI and CT 
can however, introduce systematic errors. MRI-only based RT 
eliminates these errors and reduce the time and costs of a CT 
scan. This study investigates the dosimetric differences of a 
treatment plan when the dose calculation is based on MRI as 
compared to CT.  
 
 Material and methods 
The investigated diagnostic groups are displayed in Table 1. 
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Conclusion  
The investigated DVH points show that MRI-only based RT gives 
results similar to CT based RT. The main differences are in the 
order of 2 %. In general it is necessary to correct for bone density 
although water density correction is enough in most cases. 
However, the analysis only describes similarities in DVH points 
and not in the shape of the DVH. Even though the mean 
differences are non-significant there might be unacceptable 
differences for the individual patient. The obtained results are 
consistent with those previously reported. The GVH evaluation 
support the DVH evaluation for the prostate patients. MRI-only 
based RT seems to be a feasible alternative to CT based RT. 
 
Diagnostic group 
Head & Neck 
(Oro - and hypopharynx) 
Sarcoma 
(Extremities) 
Prostate Pelvic  
(Not prostate) 
# of patients 18 6 21 9 
Delivery technique Static IMRT APPA VMAT VMAT 
Table 1 Data from each patient contains a CT scan (Phillips Big Bore 
CT), a T2 weighted MRI scan (1T Panorama Phillips), a structure set 
and a clinically approved treatment plan. The treatment planning 
system is Eclipse v.10.0 (Varian Medical Systems).  
The dose is calculated based on the MRI data as seen in Figure 1. 
The body is outlined separately on both the MRI and the CT. The 
CT based clinical treatment plan and structure set are registered 
to the corresponding MRI and the dose distribution is re-calculated 
with fixed MUs. 
Diagnostic 
group      
Volume (# of 
patients) 
Parameter MRIu[%] MRIb [%] Significant 
Prostate PTV (21) 
 
 
CTV (21) 
 
 
Rectum*(12) 
 
 
Rectum **(9) 
Dmedian 
D98% 
D2% 
Dmedian 
D98% 
D2% 
D10% 
D30% 
D60% 
D10% 
D30% 
D60% 
1.3 ± 1.4 
1.4 ± 1.9 
1.4 ± 1.3 
1.3 ± 1.4 
1.4 ± 1.5 
1.3 ± 1.4 
2.0 ± 1.7 
1.9 ± 2.5 
1.0 ± 3.0 
2.2 ± 3.0 
0.8 ± 1.5 
-0.006 ± 1.6 
-0.0002 ± 1.1 
-0.03 ± 1.7 
-0.02 ± 1.0 
-0.005 ± 1.1 
0.1 ± 1.3 
0.1 ± 1.8 
0.6 ± 1.6 
0.8 ± 2.5 
0.2 ± 3.0 
0.9 ± 3.0 
-0.008 ± 1.3 
0.7 ± 1.6 
A,B 
A,B 
A,B 
A,B 
A,B 
A,B 
NS 
NS 
NS 
NS 
NS 
NS 
Sarcoma 
(Extremities) 
PTV(6) 
 
 
CTV(6) 
 
 
Dmedian 
D98% 
D2% 
Dmedian 
D98% 
D2% 
-1.0 ± 1.8 
-2.2 ± 19.1 
-1.4 ± 3.2 
-1.2 ± 2.3 
-0.9 ± 17.7 
-1.6 ± 3.7 
-1.6 ± 3.0 
-2.3 ± 19.2 
-1.5 ± 3.6 
-1.5 ± 2.8 
-1.1 ± 17.3 
-1.6 ± 3.7 
NS 
NS 
NS 
NS 
NS 
NS 
Pelvic 
(Not prostate) 
PTV(9) 
 
 
CTV(9) 
 
 
Femur dxt.(8) 
 
Femur sin.(8) 
Dmedian 
D98% 
D2%  
Dmedian 
D98% 
D2% 
Dmean 
Dmax 
Dmean   
Dmax 
0.3 ± 1.1 
-0.8 ± 2.1 
0.7 ± 1.4       
 0.4 ± 1.1 
-0.1 ± 1.7 
0.7 ± 1.5 
0.1 ± 3.1       
0.3 ± 2.5 
0.3 ± 1.1 
0.1 ± 1.5        
-0.2 ± 1.2 
-1.2 ± 2.3 
0.7 ± 1.6       
0.9 ± 6.6 
-0.6 ± 1.5 
0.2 ± 1.8 
-0.2 ± 2.3       
-0.4 ± 1.4 
-0.5 ± 1.3 
-0.2 ± 3.3 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
Table 3 The mean value ± two standard deviations of the percentage 
differences with respect to CT. *Prescribed dose of 70 Gy. **Prescribed 
dose of 78 Gy. A: MRIu vs. CT, B: MRIu vs. MRIb. NS=Not significant.  
Results 
The results of the differences in the DVH points are displayed in 
Table 2 and Table 3. The mean differences are in the order of 
 2 %. The results of the GVH are displayed in Table 4. 
 
 
 
 
Diagnostic 
group     
Volume (# of 
patients) 
Parameter MRIu[%] MRIb [%] MRIb,c  [%] Significant 
H&N 
(Oro - and 
hypopharynx) 
PTV(18) 
 
 
CTV(18) 
 
 
Medulla(18) 
Brainstem(12) 
Parotid sin.(17) 
Parotid dxt.(18) 
Dmedian 
D98% 
D2% 
Dmedian 
D98% 
D2% 
Dmax 
Dmax 
Dmedian 
Dmedian 
1.0 ± 1.9 
1.6 ± 2.3 
1.2 ± 2.0 
1.0 ± 1.9 
1.4 ± 2.9 
1.4 ± 2.0 
0.8 ± 3.6 
-0.05 ± 20.0 
-2.0 ± 7.6 
0.8 ± 10.6 
-0.6 ± 1.2 
0.006 ± 1.8 
-0.4 ± 0.9 
-0.4 ± 1.4 
-0.2 ± 2.4 
-0.3 ± 1.1 
-1.4 ± 3 .8 
-3.3 ± 19.2 
-3.1 ± 8.0 
-0.3 ± 10.5 
0.02 ± 3.0 
-1.0 ± 2.8 
0.4 ± 4.3 
-0.05 ± 3.1 
-0.6 ± 3.2 
0.3 ± 4.5 
-1.4 ± 3.6 
-3.2 ± 19.4 
-2.1 ± 9.3 
0.8 ± 12.4 
A, B, C,E 
A,B,D,E,F  
NS 
NS 
A,B,E 
NS 
NS 
NS 
NS 
NS 
The differences in the dose distributions are quantified using 
DVH points. The reported DVH points for the target volumes are 
chosen in accordance with ICRU report 83. The DVH points for 
the organs at risk are based on our local clinical guidelines as 
well as QUANTEC.  
In addition, a gamma volume histogram (GVH) was calculated to 
quantify the fraction of the volume contained within the 20%-
isodose that fulfills the γ-criteria.  An one-way two-tailed ANOVA 
and paired t-tests are used to investigate the dose differences. 
The assumptions of the ANOVA are fulfilled since the data are 
normally distributed with constant variances. The evaluation is 
performed with a significance level of p<0.05. 
Diagnostic 
group     
Volume (# of 
patients) 
γ- criteria MRIu[%] MRIb [%] Significant 
Prostate 20%-isodose 
(18) 
 
γ 3mm/3% 
γ 2mm/3% 
γ 2mm/2% 
89.7 [79.0-99.6] 
86.7 [71.7-99.3] 
79.4 [58.6-97.7] 
90.2 [81.3-99.7] 
87.6 [76.0-99.4] 
81.5 [65.9-98.6] 
S 
S 
S 
Table 4 The mean value [range] of the percentage of points that fulfill 
the γ-criteria. S=Significant. 
Table 2 The mean value ± two standard deviations of the percentage 
differences with respect to CT. A: MRIu vs. CT, B: MRIu vs. MRIb C: MRIb vs. 
CT, D: MRIb,c vs. CT, E: MRIu vs. MRIb,c , F: MRIb vs. MRIb,c. NS=Not 
significant.  
Figure 1 MRIu: A homogeneous density assigned MRI where the 
entire body is assigned an HU equal to water. MRIb: A heterogeneous 
density assigned MRI where the CT segmented bone is transferred to 
the MRI and assigned an age dependent HU based on ICRU report 
46. For H&N patients, air cavities are also investigated (MRIb,c). 
